MedPath

Netupitant

Generic Name
Netupitant
Brand Names
Akynzeo
Drug Type
Small Molecule
Chemical Formula
C30H32F6N4O
CAS Number
290297-26-6
Unique Ingredient Identifier
7732P08TIR

Overview

Netupitant is an antiemitic drug approved by the FDA in October 2014 for use in combination with palonosetron for the prevention of acute and delayed vomiting and nausea associated with cancer chemotherapy including highly emetogenic chemotherapy. Netupitant is a neurokinin 1 receptor antagonist. The combination drug is marketed by Eisai Inc. and Helsinn Therapeutics (U.S.) Inc. under the brand Akynzeo.

Background

Netupitant is an antiemitic drug approved by the FDA in October 2014 for use in combination with palonosetron for the prevention of acute and delayed vomiting and nausea associated with cancer chemotherapy including highly emetogenic chemotherapy. Netupitant is a neurokinin 1 receptor antagonist. The combination drug is marketed by Eisai Inc. and Helsinn Therapeutics (U.S.) Inc. under the brand Akynzeo.

Indication

用于治疗和预防化疗引起的急性和延迟性恶心、呕吐。

Associated Conditions

  • Acute chemotherapy-induced nausea and vomiting
  • Delayed chemotherapy-induced nausea and vomiting

FDA Approved Products

AKYNZEO
Manufacturer:Helsinn Therapeutics (U.S.), Inc.
Route:ORAL
Strength:300 mg in 1 1
Approved: 2023/02/10
NDC:69639-101

Singapore Approved Products

AKYNZEO CAPSULES 300MG/0.5MG
Manufacturer:Helsinn Birex Pharmaceuticals Ltd. (Intermediate Netupitant Tablets and final drug product), CATALENT PHARMA SOLUTIONS LLC (Intermediate Palonosetron softgels)
Form:CAPSULE, GELATIN COATED
Strength:300mg
Online:Yes
Approved: 2016/06/08
Approval:SIN15031P

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath